Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23836183 | 0.81 | SIGMAR1 (0.52) | SIGMAR1KDM4ECYP3A4MAPTPOLB | |
| SCHEMBL7746605 | 0.80 | SIGMAR1 (0.55) | SIGMAR1KDM4ECYP3A4MAPTPOLB | |
| SCHEMBL1716115 | 0.80 | SIGMAR1 (0.55) | SIGMAR1KDM4ECYP3A4MAPTPOLB | |
| SCHEMBL7346313 | 0.80 | SIGMAR1 (0.55) | SIGMAR1KDM4ECYP3A4MAPTPOLB | |
| SCHEMBL19185547 | 0.79 | SIGMAR1 (0.48) | SIGMAR1KDM4ECYP3A4MAPTPOLB | |
| SCHEMBL9181344 | 0.78 | SIGMAR1 (0.63) | SIGMAR1KDM4ECYP3A4MAPTPOLB | |
| Hydrochloric Acid SCHEMBL10889430 | 0.78 | SIGMAR1 (0.53) | SIGMAR1KDM4ECYP3A4MAPTPOLB | |
| SCHEMBL24019759 | 0.77 | SIGMAR1 (0.47) | SIGMAR1KDM4ECYP3A4MAPTPOLB | |
| SCHEMBL22899588 | 0.76 | SIGMAR1 (0.65) | SIGMAR1KDM4ECYP3A4MAPTPOLB | |
| SCHEMBL3413593 | 0.76 | SIGMAR1 (0.65) | SIGMAR1KDM4ECYP3A4MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114195680-B | Preparation method and application of aromatic secondary diamine chain extender | 苏州湘园新材料股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| EP-0323399-B1 | OPTICAL BRIGHTENER DISPERSION | CIBA-GEIGY AG (CH) | 1993-02-17 | — | — | EP | claimed |
| CN-114195680-B | Preparation method and application of aromatic secondary diamine chain extender | 苏州湘园新材料股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117903067-A | Synthesis method of trimethoprim | 山西同济药业有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-114195680-A | Preparation method and application of aromatic diamine chain extender | 苏州湘园新材料股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021212039-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-11124497-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| EP-1370265-B1 | HIV INHIBITING PYRAZINONE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-25 | — | — | EP | disclosed |
| WO-2004009559-A2 | DIHYDROURACIL COMPOUNDS AS ANTI-ICTOGENIC OR ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-01-29 | — | — | WO | disclosed |
| EP-0066415-A2 | N-(arylthioalkyl)-N'-(aminoalkyl)ureas | A.H. ROBINS COMPANY, INCORPORATED (US) | 1982-12-08 | — | — | EP | disclosed |
| US-4052553-A | BACTERICIDE, ANTIMALARIAL | BURROUGHS WELLCOME CO. (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124497-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | SIGMAR1 4383/4885KDM4E 3119/4885CYP3A4 1077/4885 |
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH2, HRH3 | SIGMAR1 1143/4885KDM4E 1755/4885CYP3A4 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.